Nanomedicine

Biofilm-associated lung infections, particularly those caused by Pseudomonas aeruginosa in cystic fibrosis and bronchiectasis patients, represent a major therapeutic challenge. The extracellular polymeric substance (EPS) matrix, metabolic heterogeneity, and microenvironmental gradients within biofilms drastically reduce antibiotic penetration and efficacy. Nanoparticle (NP)-based therapeutics offer unique advantages, such as enhanced biofilm penetration, controlled release, and localized delivery via inhalation. This review summarizes the latest developments in the design, synthesis, and characterization of nanoparticles intended for treating biofilm-associated pulmonary infections. The discussion emphasizes materials selection, fabrication routes, and physicochemical parameters influencing antibiofilm performance, with critical perspectives on translational challenges, safety, and future directions.

Nanotechnology-based medicines (nanomedicines) are emerging as a major innovation in the field of healthcare, combining nanoscale materials with pharmaceutical sciences to improve diagnosis, treatment, and prevention of diseases. This review explores the market potential and consumer acceptance of nanotechnology-based medicines. The nanomedicine market is expected to grow substantially due to increased prevalence of chronic diseases, advancements in targeted drug delivery, and rising investment in research and development.4 However, consumer acceptance is influenced by factors such as safety concerns, cost, ethical implications, and regulatory uncertainty. This paper highlights market dynamics, regional growth, challenges, and recommendations to improve acceptance and commercialization of nanomedicine. Despite these advancements, widespread consumer acceptance of nanomedicines remains influenced by several factors, including safety concerns, ethical considerations, high production costs, and lack of standardized regulatory frameworks. Public perception and awareness also play a critical role in determining market success. Furthermore, regional disparities in access to advanced healthcare technologies, limited infrastructure, and challenges in large-scale manufacturing hinder commercialization. This paper highlights current trends in nanomedicine development, market drivers, and barriers affecting its acceptance. It also discusses the potential impact of nanotechnology on personalized medicine and the pharmaceutical industry’s evolution. To enhance consumer trust and promote broader adoption, there is a need for transparent regulatory policies, ethical guidelines, and extensive clinical evaluation to ensure safety and efficacy. ed medicines hold the review concludes that with proper governance and technological refinement, nanotechnology-bas immense promise for transforming global healthcare systems.

Cancer is the leading cause of mortality worldwide. Treating the cancer is one of the major challenges in modern science as the drug delivery to solid tumors is a seminal challenge to develop more effective cancer therapies. A well-designed drug delivery system can potentially enhance the efficacy of a treatment by improving drug accumulation in the tumor. Application of nanotechnology to prevent and treat the cancer disease is known as nanomedicine. Cancer diagnosis and treatment can be achieved to a greater extent by the application of nanotechnology principles to biomedicine. Over these years targeted treatment for cancer has been greatly improved by the approaches based on nanotechnology. Nanoparticles have the potential to increase the specificity in treating cancer cells while leaving the healthy cells. The goal of this review is to discuss the current state of nanomedicine in the field of cancer detection and the subsequent application of nanotechnology to treat cancer by using nanoparticles such as dendrimers, quantum dots, nanocells, nanocrystals, and nanoshells for the detection and treatment of cancer.

Solid lipid nanoparticles (SLNs) have emerged as a forefront drug delivery system with diverse potential applications in pharmaceutical and cosmeceutical research, nanomedicine and other allied branches of science. Recently, increasing attention has been focused on these SLNs as colloidal drug carriers for incorporating hydrophilic or lipophilic drugs. Proteins and antigens intended for therapeutic purposes can also be incorporated or adsorbed onto SLNs, and further administered by parenteral route or by alternative routes such as oral, nasal and pulmonary etc. Due to their unique size dependent properties SLNs offer possibility to develop new therapeutics. The ability to incorporate drugs into these nanocarriers offers a new prototype in drug delivery that could use for drug targeting. Hence SLNs hold great promise for reaching the goal of controlled and site specific drug delivery and hence attracted wide attention of researchers. Also the problems associated with conventional chemotherapy can be overcome by encapsulating them in SLNs. The present review focuses on SLNs brief introduction, utility in terms of their advantages, production methodology, characterization and applications and their possible remedies. Further investigation and research related to SLNs may open new vistas in nanotechnology and in therapy of multifaceted diseases.